Details of the Drug Reposition

General Information of This Drug (ID: DMK3U1X)

Drug Name
ALT-803   DMK3U1X
Synonyms IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 2 [1]
Bladder cancer DISUHNM0 2C94 Phase 2 [2]
------------------------------------------------------------------------------------
3 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [3]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1/2 [4]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 1/2 [4]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Human immunodeficiency virus infection DISRNAI4 1C62 Phase 1 [5]
Multiple myeloma DISEWP9B 2A83 Phase 1 [2]
Pancreatic cancer DISJC981 2C10 Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03050216) QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02384954) ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)